| Jul 31 |
Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023
|
| Jun 3 |
Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
|
| May 24 |
Celularity announces receipt of Nasdaq notice regarding late Form 10-Q filing
|
| May 24 |
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
|
